The US FDA has scheduled a Psychopharmacologic Drugs Advisory Committee (PDAC) Meeting for Tuesday, December 1, 2015 to discuss new drug application (NDA) 21164, gepirone hydrochloride extended-release tablets, submitted by Fabre-Kramer Pharmaceuticals, Inc., for the proposed indication of major depressive disorder.